Full metadata record

DC Field Value Language
dc.contributor.authorLee, Hyojin-
dc.contributor.authorKim, Tae Hee-
dc.contributor.authorPark, Daechan-
dc.contributor.authorJang, Mihue-
dc.contributor.authorChung, Justin J.-
dc.contributor.authorKim, Soo Hyun-
dc.contributor.authorKim, Sang-Heon-
dc.contributor.authorLee, Kwan Hyi-
dc.contributor.authorJung, Youngmee-
dc.contributor.authorOh, Seung Ja-
dc.date.accessioned2024-01-19T17:04:32Z-
dc.date.available2024-01-19T17:04:32Z-
dc.date.created2021-09-05-
dc.date.issued2020-07-
dc.identifier.issn1999-4923-
dc.identifier.urihttps://pubs.kist.re.kr/handle/201004/118462-
dc.description.abstractMembrane receptors overexpressed in diseased states are considered novel therapeutic targets. However, the single targeting approach faces several fundamental issues, such as poor efficacy, resistance, and toxicity. Here, we report a dual-targeting strategy to enhance anti-cancer efficacy via synergistic proximity interactions between therapeutics and two receptor proteins. Importantly, we report the first finding of an interaction between c-Met and nucleolin and demonstrate the therapeutic value of targeting the interaction between them. Bispecific nanocarriers densely grafted with anti-c-Met and -nucleolin aptamer increased the local concentration of aptamers at the target sites, in addition to inducing target receptor clustering. It was also demonstrated that the simultaneous targeting of c-Met and nucleolin inhibited the cellular functions of the receptors and increased anti-cancer efficacy by altering the cell cycle. Our findings pave the way for the development of an effective combinatorial treatment based on nanoconstruct-mediated interaction between receptors.-
dc.languageEnglish-
dc.publisherMDPI-
dc.subjectDNA APTAMER-
dc.subjectNUCLEOLIN-
dc.subjectAS1411-
dc.subjectTHERAPY-
dc.subjectOLIGONUCLEOTIDES-
dc.subjectNANOPARTICLES-
dc.subjectCHEMOTHERAPY-
dc.subjectAGENT-
dc.titleCombinatorial Inhibition of Cell Surface Receptors Using Dual Aptamer-Functionalized Nanoconstructs for Cancer Treatment-
dc.typeArticle-
dc.identifier.doi10.3390/pharmaceutics12070689-
dc.description.journalClass1-
dc.identifier.bibliographicCitationPHARMACEUTICS, v.12, no.7-
dc.citation.titlePHARMACEUTICS-
dc.citation.volume12-
dc.citation.number7-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.identifier.wosid000554212800001-
dc.identifier.scopusid2-s2.0-85088276178-
dc.relation.journalWebOfScienceCategoryPharmacology & Pharmacy-
dc.relation.journalResearchAreaPharmacology & Pharmacy-
dc.type.docTypeArticle-
dc.subject.keywordPlusDNA APTAMER-
dc.subject.keywordPlusNUCLEOLIN-
dc.subject.keywordPlusAS1411-
dc.subject.keywordPlusTHERAPY-
dc.subject.keywordPlusOLIGONUCLEOTIDES-
dc.subject.keywordPlusNANOPARTICLES-
dc.subject.keywordPlusCHEMOTHERAPY-
dc.subject.keywordPlusAGENT-
dc.subject.keywordAuthorcombinatorial treatment-
dc.subject.keywordAuthoraptamer-
dc.subject.keywordAuthorgold nanoconstructs-
dc.subject.keywordAuthorsurface receptor-
dc.subject.keywordAuthorreceptor interaction-
Appears in Collections:
KIST Article > 2020
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE